Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Venlafaxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 8/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Venlafaxine SCHEMBL1560692 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL10614031 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL27838459 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL35154 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL10616028 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| (S)-Venlafaxine SCHEMBL3644633 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| (S)-Venlafaxine SCHEMBL4512264 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL3863025 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL6554144 | 0.99 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL6126163 | 0.99 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3LMNACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5753 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250136548-A1 | FUNCTIONALIZED ALKYLAMINES | TERRAN BIOSCIENCES INC (US) | 2025-05-01 | — | — | US | claimed |
| US-20250122164-A1 | N,N-DIMETHYLAMPHETAMINE ANALOGS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-17 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| CN-113573723-B | Synthetic neuromodulatory peptides | 拉托科公司 | 2024-12-03 | — | — | CN | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240307386-A1 | NOVEL METHODS | INTRA-CELLULAR THERAPIES, INC. | 2024-09-19 | — | — | US | claimed |
| WO-2003039519-A2 | DUAL CONTROLLED RELEASE DOSAGE FORM | OSMOTICA CORP. (VG) | 2003-05-15 | — | — | WO | claimed |
| US-6541523-B2 | Especially treating fibromyalgia, chronic fatigue syndrome, psychogenic pain and chromic pain | VELA PHARMACEUTICALS, INC. | 2003-04-01 | — | — | US | claimed |
| EP-1253915-A1 | METHOD FOR TREATING STRESS WITH A PRECURSOR OF SEROTONIN | Massachusetts Institute of Technology (US) | 2002-11-06 | — | — | EP | claimed |
| WO-2002085297-A2 | COMPOSITIONS & FORMULATIONS WITH A NON-GLUCOCORTICOID STEROID &/OR A UBIQUINONE & KIT FOR TREATMENT OF RESPIRATORY & LUNG DISEASE | EAST CAROLINA UNIVERSITY (US) | 2002-10-31 | — | — | WO | claimed |
| US-6395788-B1 | FATIGUE, CHRONIC FATIGUE SYNDROME, PAIN, AND AUTOIMMUNE DISEASE TREATMENT; SIDE EFFECT REDUCTION | VELA PHARMACEUTICALS, INC. | 2002-05-28 | — | — | US | claimed |
| EP-1202722-A1 | USES COMPOSITIONS FOR TREATING OR PREVENTING SLEEP DISTURBANCES USING VERY LOW DOSES OF CYCLOBENZAPRINE | Vela Pharmaceuticals Inc. (US) | 2002-05-08 | — | — | EP | claimed |
| US-20010046988-A1 | Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine | VELA PHARMACEUTICALS, INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001054681-A2 | COMPOSITION FOR TREATMENT OF STRESS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-08-02 | — | — | WO | claimed |
| WO-2001012175-A1 | USES COMPOSITIONS FOR TREATING OR PREVENTING SLEEP DISTURBANCES USING VERY LOW DOSES OF CYCLOBENZAPRINE | VELA PHARMACEUTICALS INC. (US) | 2001-02-22 | — | — | WO | claimed |
| WO-2001007397-A1 | VENLAFAXINE PRODUCTION PROCESS | MEDICHEM S.A. (ES) | 2001-02-01 | — | — | WO | claimed |